Category

HIV-AIDS

Home > Therapeutic Areas > HIV-AIDS

Coll P, Jarrín I, Martínez E, Martínez-Sesmero JM, Domínguez-Hernández R, Castro-Gómez A, Casado MA

 

 

Achieving the UNAIDS goals by 2030 in people living with HIV: A simulation model to support the prioritization of health care interventions
Enfermedades Infecciosas y Microbiología Clínica. Doi.org/10.1016/j.eimc.2022.07.012

Estrada V, Górgolas M, Peña JA, Tortajada E, Castro A, Presa M, Oyagüez I

 

 

Epidemiologic and economic analysis of rapid antiretroviral therapy initiation with bictegravir/emtricitabine/tenofovir alafenamide in Spain
PharmacoEconomics – Open
https://doi.org/10.1007/s41669-022-00322-w

Moltó J, González J, Navarro C, Castro A, Presa M, Oyagüez I

 

 

Cribado dirigido del Virus de la Inmunodeficiencia Humana en los servicios de urgencias en España: análisis de las consecuencias epidemiológicas y económicas
Emergencias 2022;34:21-28

Moltó J, González J, Navarro C, Presa M, Casado MA

 

 

Epidemiologic and economic analysis of targeted screening for human immunodeficiency virus in emergency department in Spain
Congress International Health Economics Association (IHEA). 12-15 jul 2021

Estrada V, Górgolas M, Peña JA, Tortajada E, Presa M, Casado MA

 

 

Epidemiologic and economic analysis of early antiretroviral therapy with bictegravir/embtricitabine/tenofovir alafenamide in Spain
Congress International Health Economics Association (IHEA). 12-15 jul 2021

Coll P, Jarrín I, Martínez E, Martínez-Sesmero JM, Domínguez-Hernández R, Casado MA

 

 

Achieving 2030 UNAIDS goals in human immunodeficiency virus individuals: a simulation model to prioritize interventions for decision making
23rd Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Virtual. 16-19 nov 2020

POSTER

Podzamczer D, Rozas N, Domingo P, Miralles C, den Eynde EV, Romero A, Deig E, Knobel H, Pasquau J, Antela A, Clotet B, Geijo P, de Castro ER, Casado MA, Muñoz A, Casado A

 

Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA®, Because of a Previous Intolerance to CART. PRO-STR Study
Current HIV Research 2018, 16, 425-435

Ocampo A, Domingo P, Fernández P, Diz J, Barberá JR, Sepúlveda MA, Salgado X, Rodriguez M, Santos J, Yzusqui M, Mayorga MI, Lorenzo JF, Bahamonde A, Bachiller P, Martínez E, Rozas N, Torres C, Muñoz A, Casado A, Podzamczer D

 

Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to RPV/FTC/TDF due to intolerance to previous cART: the PRO-STR study
Journal Antimicrobial Chemotherapy.Doi: 10.1093/jac/dky175

Ocampo A, Domingo P, Fernández P, Diz J, Barberá JR, Sepúlveda MA, Salgado X, Rodriguez M, Santos J, Yzusqui M, Castaño M, Lorenzo JF, Bahamonde A, Bachiller P, Martínez E, Rozas N, Torres C, Muñoz A, Podzamczer D

 

Lipid Changes And Tolerability In A Cohort Of Adult HIV-infected Patients Switching To RPV/FTC/TDF, Due To Intolerance To Previous cART. A Substudy Of PRO-STR Study
VII Congreso Nacional de Gesida. Madrid, Spain. 1-4 dic 2015